Garcia-Zamalloa Alberto, Basauri Begoña, Urcelay Goretti, Sainz Adriana
Internal Medicine Service, Mendaro Hospital, Osakidetza/Basque Health Service, Gipuzkoa, Spain.
Pleural-Respiratory Research Unit, Biodonostia Health Research Institute, Gipuzkoa, Spain.
Eur J Case Rep Intern Med. 2023 Jun 7;10(7):003921. doi: 10.12890/2023_003921. eCollection 2023.
Dasatinib is a tyrosine kinase inhibitor used for treatment of some specific types of leukaemia. The development of pleural effusion is a known adverse effect of dasatinib and chylothorax is exceptional. No case has been reported beyond 5 years of treatment and extensive search for an alternative diagnosis is currently suggested in such scenario. The underlying mechanism is not currently clear. We describe a woman on dasatinib treatment for more than 10 years who developed chylothorax. Drug withdrawal resolved the chylous pleural effusion. We were able to find 14 additional cases of dasatinib-related chylothorax reported up until now.
Dasatinib is a tyrosine kinase inhibitor used for the treatment of some specific types of leukaemia.Development of pleural effusion is a potential adverse effect, mostly in the first 6 years of treatment. The underlying mechanism is not known.Chylothorax is exceptional, and no case had been described beyond 5 years of treatment; our case would be the first one. We found 14 additional cases of dasatinib-related chylothoraces in a PubMed research.
达沙替尼是一种用于治疗某些特定类型白血病的酪氨酸激酶抑制剂。胸腔积液的发生是达沙替尼已知的不良反应，而乳糜胸则较为罕见。治疗超过5年的病例尚未见报道，目前在这种情况下建议广泛寻找其他诊断方法。其潜在机制目前尚不清楚。我们描述了一名接受达沙替尼治疗超过10年的女性，她出现了乳糜胸。停药后乳糜性胸腔积液得以缓解。截至目前，我们还能找到另外14例已报道的与达沙替尼相关的乳糜胸病例。
达沙替尼是一种用于治疗某些特定类型白血病的酪氨酸激酶抑制剂。胸腔积液的发生是一种潜在的不良反应，主要发生在治疗的前6年。其潜在机制尚不清楚。乳糜胸较为罕见，治疗超过5年的病例未见描述；我们的病例将是首例。我们在PubMed研究中又发现了14例与达沙替尼相关的乳糜胸病例。
